Global Research Trends in Immunoconjugates for Cervical Cancer: 2015–2024

Overview

Research on immunoconjugates for cervical cancer has rapidly increased since 2021, reflecting a shift toward clinical translation. Key developments include the approval of tisotumab vedotin and emerging clinical trials evaluating combination therapies, highlighting evolving therapeutic strategies and safety considerations.

Background

Cervical cancer remains a significant global health burden, especially in low- and middle-income countries, with limited treatment options for advanced or recurrent disease. Antibody-drug conjugates (immunoconjugates) offer targeted delivery of cytotoxic agents to tumor cells, potentially improving efficacy and reducing toxicity compared to conventional chemotherapy. Tisotumab vedotin, targeting tissue factor, is the first FDA-approved immunoconjugate for recurrent or metastatic cervical cancer, demonstrating clinical activity and manageable safety profiles. Ongoing research explores additional targets and combination regimens to overcome resistance and enhance outcomes.

Data Highlights

Key Findings

• Publication output on immunoconjugates for cervical cancer markedly increased after 2021, indicating growing clinical interest.
• Five thematic research clusters identified: clinical safety/toxicity, hematologic malignancy translational influences, preclinical mechanisms, gynecologic oncology applications, and clinical trial design.
• Tisotumab vedotin targets tissue factor, overexpressed in up to 95% of cervical cancers, and has demonstrated clinical efficacy with manageable toxicities including ocular events and peripheral neuropathy.
• Emerging immunoconjugates such as sacituzumab govitecan and trastuzumab deruxtecan show promising response rates in recurrent/metastatic cervical cancer.
• Challenges include resistance mechanisms, tumor heterogeneity, and adverse effects necessitating biomarker-driven approaches and combination therapies with immune checkpoint inhibitors.
• Bibliometric analysis reveals a temporal shift from mechanistic studies to clinically oriented research focusing on actionable targets and safety optimization.

Clinical Implications

Clinicians should consider immunoconjugates like tisotumab vedotin as viable options for patients with recurrent or metastatic cervical cancer, recognizing the importance of monitoring for ocular toxicity and neuropathy. Ongoing trials combining immunoconjugates with chemotherapy or immunotherapy may expand therapeutic options and improve response rates. Biomarker assessment and vigilance for adverse effects are critical to optimize patient outcomes.

Conclusion

The field of immunoconjugates in cervical cancer has matured rapidly, transitioning from foundational research to clinical application with promising targeted therapies. Continued translational efforts and combination strategies hold potential to improve prognosis in this challenging disease.

References

1. InnovaTV 204 Trial Results and FDA Approval (2021) -- Tisotumab Vedotin in Cervical Cancer
2. Phase II Trial of Sacituzumab Govitecan in Recurrent Cervical Cancer (2023)
3. DESTINY-PanTumor02 Study -- Trastuzumab Deruxtecan Activity in Solid Tumors
4. Global Cervical Cancer Epidemiology and Treatment Landscape (2022)